Last update 27 Mar 2025

Brivekimig

Overview

Basic Info

Drug Type
Nanobody
Synonyms
Anti-TNFa and OX40L (Sanofi), Anti-TNFa/OX40L (Sanofi), SAR 442970
+ [1]
Action
inhibitors
Mechanism
OX40L inhibitors(Tumor necrosis factor ligand superfamily member 4 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 2
Canada
28 Feb 2025
Diabetes Mellitus, Type 1Phase 2
Chile
28 Feb 2025
Glomerulosclerosis, Focal SegmentalPhase 2
United States
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
China
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
Canada
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
Chile
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
France
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
Germany
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
Greece
19 Dec 2024
Glomerulosclerosis, Focal SegmentalPhase 2
Italy
19 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free